DK161968C - Analogifremgangsmaade til fremstilling af imidazo-pyrazolo-pyrimidiner eller farmaceutisk acceptable salte deraf - Google Patents

Analogifremgangsmaade til fremstilling af imidazo-pyrazolo-pyrimidiner eller farmaceutisk acceptable salte deraf

Info

Publication number
DK161968C
DK161968C DK227183A DK227183A DK161968C DK 161968 C DK161968 C DK 161968C DK 227183 A DK227183 A DK 227183A DK 227183 A DK227183 A DK 227183A DK 161968 C DK161968 C DK 161968C
Authority
DK
Denmark
Prior art keywords
pyrazolo
pyrimidines
imidazo
analogue
preparation
Prior art date
Application number
DK227183A
Other languages
Danish (da)
English (en)
Other versions
DK227183D0 (da
DK227183A (da
DK161968B (da
Inventor
Horace A Dewald
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of DK227183D0 publication Critical patent/DK227183D0/da
Publication of DK227183A publication Critical patent/DK227183A/da
Publication of DK161968B publication Critical patent/DK161968B/da
Application granted granted Critical
Publication of DK161968C publication Critical patent/DK161968C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK227183A 1982-05-24 1983-05-20 Analogifremgangsmaade til fremstilling af imidazo-pyrazolo-pyrimidiner eller farmaceutisk acceptable salte deraf DK161968C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/381,484 US4469868A (en) 1982-05-24 1982-05-24 Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines
US38148482 1982-05-24

Publications (4)

Publication Number Publication Date
DK227183D0 DK227183D0 (da) 1983-05-20
DK227183A DK227183A (da) 1983-11-25
DK161968B DK161968B (da) 1991-09-02
DK161968C true DK161968C (da) 1992-02-03

Family

ID=23505215

Family Applications (1)

Application Number Title Priority Date Filing Date
DK227183A DK161968C (da) 1982-05-24 1983-05-20 Analogifremgangsmaade til fremstilling af imidazo-pyrazolo-pyrimidiner eller farmaceutisk acceptable salte deraf

Country Status (22)

Country Link
US (1) US4469868A (es)
EP (1) EP0095289B1 (es)
JP (1) JPS58210087A (es)
KR (1) KR870000931B1 (es)
AR (1) AR240941A1 (es)
AT (1) ATE24510T1 (es)
AU (1) AU553708B2 (es)
CA (1) CA1210393A (es)
DE (1) DE3368635D1 (es)
DK (1) DK161968C (es)
ES (4) ES8407051A1 (es)
FI (1) FI74012C (es)
GR (1) GR79262B (es)
HK (1) HK102989A (es)
HU (1) HU187913B (es)
IE (1) IE55111B1 (es)
IL (1) IL68360A (es)
NO (1) NO160444C (es)
NZ (1) NZ204321A (es)
PH (1) PH18454A (es)
PT (1) PT76745B (es)
ZA (1) ZA832637B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000192A1 (en) * 1986-06-26 1988-01-14 Warner-Lambert Company 5-SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDIN-7-ONES
JP2008520749A (ja) * 2004-11-23 2008-06-19 レディ ユーエス セラピューティックス， インコーポレイテッド 新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
MX2011005936A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5911854B2 (ja) 2010-05-31 2016-04-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9802937B2 (en) * 2011-04-21 2017-10-31 Origenis Gmbh Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
WO2014127331A1 (en) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Novel uses
JP2016518343A (ja) 2013-03-15 2016-06-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
AU2014234990B2 (en) 2013-03-15 2017-11-16 Intra-Cellular Therapies, Inc. Organic compounds
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422807A (de) * 1963-08-16 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung von Imidazo- und Pyrimidochinazolinen
US3313815A (en) * 1964-05-04 1967-04-11 Sterling Drug Inc 8-chloropyrazolo-[1, 5-c]quinazoline derivatives and methods of preparing same
US3309369A (en) * 1966-04-11 1967-03-14 Wander Ag Dr A Imidazo- and pyrimido-quinazolines
US3594379A (en) * 1968-09-16 1971-07-20 Sandoz Ag 2,3-dihydroimidazo(1,2-c)quinazolines
DE2058501A1 (de) * 1970-11-27 1972-05-31 Bayer Ag Verfahren zur Herstellung von neuen N-verbrueckten bicyclischen Heteroaromaten
GB1347493A (en) * 1971-02-11 1974-02-27 Aspro Nicholas Ltd Benzazine derivatives
US3984556A (en) * 1973-01-19 1976-10-05 Sandoz, Inc. Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure
JPS516993A (en) * 1974-07-05 1976-01-20 Dainippon Pharmaceutical Co Adeninjudotaino seiho
JPS5398997A (en) * 1977-02-09 1978-08-29 Sumitomo Chem Co Ltd Fused pyridine derivertives and process for their preparation
US4206123A (en) * 1977-10-31 1980-06-03 Mccall John M Isothiochroman
US4250181A (en) * 1977-10-31 1981-02-10 The Upjohn Company Methods of treating psychosis
US4247553A (en) * 1977-10-31 1981-01-27 The Upjohn Company Methods of treating psychosis
US4192803A (en) * 1978-09-15 1980-03-11 American Cyanamid Company 5H-Pyrrolo[2,1-c][1,4]benzodiazepine derivatives
CA1141384A (en) * 1978-11-01 1983-02-15 Morton Harfenist Pharmaceutical heterocyclic comounds, preparation, use and intermediates therefor and their preparations
CH643263A5 (de) * 1979-05-11 1984-05-30 Sandoz Ag Benzodiazepine, ihre herstellung und verwendung.
HU178523B (en) * 1979-05-18 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for preparing new pyrazolo-quinazoline derivatives
US4230707A (en) * 1979-08-27 1980-10-28 Warner-Lambert Company Oxo-pyrido[1,2-a]thienopyrimidine compounds and methods for their production
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
US4396770A (en) * 1982-04-09 1983-08-02 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
US4415581A (en) * 1982-04-09 1983-11-15 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines to treat psychoses
US4374245A (en) * 1982-04-09 1983-02-15 Hoechst-Roussel Pharmaceuticals Inc. 8-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
US4409230A (en) * 1982-04-09 1983-10-11 Hoechst-Roussel Pharmaceuticals Inc. Pharmaceutical compositions and methods employing 8-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-1-phenyl-1,3,8-triazaspiro-[4.]decan-4-one and derivatives thereof
US4390544A (en) * 1982-04-09 1983-06-28 Hoechst-Roussel Pharmaceuticals Inc. {1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(2-oxo-1-benzimidazolinyl}p
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol

Also Published As

Publication number Publication date
ATE24510T1 (de) 1987-01-15
JPH0320395B2 (es) 1991-03-19
FI831742L (fi) 1983-11-25
PT76745A (en) 1983-06-01
NZ204321A (en) 1986-06-11
JPS58210087A (ja) 1983-12-07
ES8506004A1 (es) 1985-06-16
ES522617A0 (es) 1984-09-01
ES529372A0 (es) 1985-06-16
EP0095289B1 (en) 1986-12-30
ZA832637B (en) 1984-01-25
IL68360A0 (en) 1986-10-31
IL68360A (en) 1986-10-31
IE55111B1 (en) 1990-06-06
AR240941A1 (es) 1991-03-27
DK227183D0 (da) 1983-05-20
DK227183A (da) 1983-11-25
NO160444B (no) 1989-01-09
FI831742A0 (fi) 1983-05-18
ES529373A0 (es) 1985-06-16
PT76745B (en) 1986-04-21
ES8506315A1 (es) 1985-07-01
US4469868A (en) 1984-09-04
EP0095289A3 (en) 1984-09-05
AR240941A2 (es) 1991-03-27
AU1342783A (en) 1983-12-01
KR870000931B1 (ko) 1987-05-11
DK161968B (da) 1991-09-02
GR79262B (es) 1984-10-22
HK102989A (en) 1990-01-05
AU553708B2 (en) 1986-07-24
ES8407051A1 (es) 1984-09-01
FI74012B (fi) 1987-08-31
HU187913B (en) 1986-03-28
KR840004756A (ko) 1984-10-24
CA1210393A (en) 1986-08-26
NO831792L (no) 1983-11-25
NO160444C (no) 1989-04-19
ES8506019A1 (es) 1985-06-16
DE3368635D1 (en) 1987-02-05
ES529371A0 (es) 1985-07-01
EP0095289A2 (en) 1983-11-30
FI74012C (fi) 1987-12-10
IE830822L (en) 1983-11-24
PH18454A (en) 1985-07-18

Similar Documents

Publication Publication Date Title
DK160940C (da) Analogifremgangsmaade til fremstilling af benzoheterocycliske forbindelser eller farmaceutisk acceptable salte deraf
DK161770C (da) Analogifremgangsmaade til fremstilling af cyklobutylaminderivater eller farmaceutisk acceptable salte deraf
DK152495C (da) Analogifremgangsmaade til fremstilling af n2-arylsulfonyl-l-argininamider eller farmaceutisk tolerable salte deraf
DK163359C (da) Analogifremgangsmaade til fremstilling af n-imidazolylderivater af bicycliske forbindelser eller pharmaceutisk acceptable salte deraf
DK161968C (da) Analogifremgangsmaade til fremstilling af imidazo-pyrazolo-pyrimidiner eller farmaceutisk acceptable salte deraf
DK148537C (da) Analogifremgangsmaade til fremstilling af 3-aminopyridazinforbindelser eller farmaceutisk acceptable salte deraf
DK152114C (da) Analogifremgangsmaade til fremstilling af propenylaminer eller farmaceutisk acceptable salte deraf
DK552581A (da) Fremgangsmaade til fremstilling af 3-pyridylaklyl-indol-forbindelser eller farmaceutisk acceptable salte deraf
DK157862C (da) Analogifremgangsmaade til fremstilling af imidazolylphenylamidiner eller farmaceutisk acceptable syreadditionssalte deraf
DK70083A (da) Fremgangsmaade til fremstilling af pyrroleddikesyreamider eller salte deraf
DK158306C (da) Analogifremgangsmaade til fremstilling af substituerede pyridylallylforbindelser eller farmaceutisk acceptable salte deraf
DK162166C (da) Analogifremgangsmaade til fremstilling af (2s)-isomere af 2-oe4-(2-hydroxycyclopentan-1-ylmethyl)phenylaapropionsyre eller farmaceutisk acceptable salte deraf
DK161699C (da) Analogifremgangsmaade til fremstilling af 4-aryl-4-piperidincarbinoler eller farmaceutisk acceptable salte deraf
DK158658C (da) Analogifremgangsmaade til fremstilling af 9-aminoalkylfluorener eller farmaceutisk acceptable salte deraf
DK413883D0 (da) Fremgangsmade til fremstilling af c-20-modificerede macrolid-derivater eller farmaceutisk acceptable salte deraf
DK145263C (da) Analogifremgangsmaade til fremstilling af imidazothiaziner eller farmaceutisk acceptable salte deraf
DK152491C (da) Analogifremgangsmaade til fremstilling af esterholdige phenoxypropanolaminer eller farmaceutisk anvendelige salte deraf
DK162102C (da) Analogifremgangsmaade til fremstilling af 3-o-(beta-d-glucoronopyranosyl)-sojasapogenol b eller farmaceutisk acceptable salte deraf
DK157023C (da) Analogifremgangsmaade til fremstilling af imidazodiazepiner eller farmaceutisk acceptable syreadditionssalte deraf
DK148019C (da) Analogifremgangsmaade til fremstilling af 2-pyridylaminobenzoesyrer eller farmaceutisk acceptable salte deraf
DK150521C (da) Analogifremgangsmaade til fremstilling af n2-arylsulfonyl-l-argininamider eller farmaceutisk acceptable salte deraf
DK149823C (da) Fremgangsmaade til fremstilling af kijanimicin eller farmaceutisk acceptable salte heraf
DK151254C (da) Analogifremgangsmaade til fremstilling af 2-hydroxymethyl-pyrazin-derivater eller farmaceutisk acceptable salte deraf
DK164786C (da) Analogifremgangsmaade til fremstilling af benzazolderivater eller salte deraf
DK210183D0 (da) Fremgangsmade til fremstillng af piperidinoquinazolin-forbindelser eller farmaceutisk acceptable salte deraf

Legal Events

Date Code Title Description
PBP Patent lapsed